{"id":57727,"date":"2026-02-24T17:27:06","date_gmt":"2026-02-24T09:27:06","guid":{"rendered":"https:\/\/flcube.com\/?p=57727"},"modified":"2026-02-24T17:27:06","modified_gmt":"2026-02-24T09:27:06","slug":"trinomabs-retavibart-nda-accepted-by-nmpa-first-long-acting-rsv-mab-for-infant-protection-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57727","title":{"rendered":"Trinomab&#8217;s Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China"},"content":{"rendered":"\n<p><strong>Zhuhai Trinomab Biopharmaceutical Co., Ltd.<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its <strong>New Drug Application (NDA)<\/strong> for <strong>Retavibart Injection<\/strong> (formerly TNM001 Injection), a <strong>recombinant long\u2011acting fully human monoclonal antibody<\/strong> targeting <strong>respiratory syncytial virus (RSV)<\/strong>. The product is specifically designed for <strong>infants under one year old<\/strong>, including high\u2011risk populations prone to severe RSV infections, for the <strong>prevention of lower respiratory tract infections<\/strong> caused by the virus.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Zhuhai Trinomab Biopharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Retavibart Injection (formerly TNM001 Injection)<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NDA accepted by NMPA<\/td><\/tr><tr><td><strong>Application Date<\/strong><\/td><td>13\u202fFeb\u202f2026<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Recombinant long\u2011acting fully human anti\u2011RSV monoclonal antibody<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Infants under 1 year old (including high\u2011risk groups)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Prevention of RSV lower respiratory tract infections<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Single intramuscular injection<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-iii-study\">Clinical Evidence \u2013 Phase III Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Retavibart Result<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Efficacy<\/strong><\/td><td>Significant reduction in RSV lower respiratory tract infections within 150 days<\/td><td>Demonstrates robust seasonal protection<\/td><\/tr><tr><td><strong>Severe Disease Prevention<\/strong><\/td><td>Particularly outstanding protection against severe RSV lower respiratory tract infections<\/td><td>Addresses highest unmet medical need in infant population<\/td><\/tr><tr><td><strong>Duration of Protection<\/strong><\/td><td>Full RSV epidemic season coverage from single dose<\/td><td>Eliminates need for repeat dosing during season<\/td><\/tr><tr><td><strong>Administration Convenience<\/strong><\/td><td>Single intramuscular injection<\/td><td>Aligns with infant care workflows and compliance needs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-retavibart\">Product Profile \u2013 Retavibart<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Long\u2011acting fully human anti\u2011RSV monoclonal antibody<\/strong> providing passive immunization<\/li>\n\n\n\n<li><strong>Target:<\/strong> Respiratory syncytial virus (RSV) \u2013 leading cause of infant hospitalization globally<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>Single\u2011dose seasonal protection<\/strong> vs. multi\u2011dose regimens or monthly injections required by competing products<\/li>\n\n\n\n<li><strong>Clinical Convenience:<\/strong> One intramuscular injection covers entire RSV epidemic season, reducing healthcare burden and improving parental compliance<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China RSV Prevention Market:<\/strong> RSV is the <strong>leading cause of lower respiratory tract infections<\/strong> in infants under one year, with significant hospitalization burden. Current prevention options in China are limited, creating substantial market opportunity.<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Retavibart&#8217;s <strong>long\u2011acting profile<\/strong> and <strong>single\u2011dose convenience<\/strong> differentiate it from existing monoclonal antibody therapies requiring monthly administration, potentially capturing significant market share upon approval.<\/li>\n\n\n\n<li><strong>Public Health Value:<\/strong> The product addresses a <strong>critical pediatric unmet need<\/strong>, with potential for inclusion in national immunization programs or seasonal prophylaxis guidelines for high\u2011risk infants.<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> NDA acceptance validates Trinomab&#8217;s <strong>independent R&amp;D capabilities<\/strong> and positions the company as an emerging player in the infectious disease biologics space.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding NMPA review timelines, approval expectations, and commercial potential for Retavibart. Actual results may differ due to risks including regulatory review outcomes, manufacturing scale\u2011up, and competitive market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China&#8217;s National Medical Products Administration (NMPA) has accepted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57729,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[1848],"class_list":["post-57727","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-trinomab-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Trinomab&#039;s Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China&#039;s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Retavibart Injection (formerly TNM001 Injection), a recombinant long\u2011acting fully human monoclonal antibody targeting respiratory syncytial virus (RSV). The product is specifically designed for infants under one year old, including high\u2011risk populations prone to severe RSV infections, for the prevention of lower respiratory tract infections caused by the virus.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57727\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trinomab&#039;s Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China\" \/>\n<meta property=\"og:description\" content=\"Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China&#039;s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Retavibart Injection (formerly TNM001 Injection), a recombinant long\u2011acting fully human monoclonal antibody targeting respiratory syncytial virus (RSV). The product is specifically designed for infants under one year old, including high\u2011risk populations prone to severe RSV infections, for the prevention of lower respiratory tract infections caused by the virus.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57727\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T09:27:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Trinomab&#8217;s Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China\",\"datePublished\":\"2026-02-24T09:27:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727\"},\"wordCount\":445,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2404.webp\",\"keywords\":[\"Trinomab Biotech\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57727#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57727\",\"name\":\"Trinomab's Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2404.webp\",\"datePublished\":\"2026-02-24T09:27:06+00:00\",\"description\":\"Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Retavibart Injection (formerly TNM001 Injection), a recombinant long\u2011acting fully human monoclonal antibody targeting respiratory syncytial virus (RSV). The product is specifically designed for infants under one year old, including high\u2011risk populations prone to severe RSV infections, for the prevention of lower respiratory tract infections caused by the virus.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57727\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/2404.webp\",\"width\":1080,\"height\":608,\"caption\":\"Trinomab's Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57727#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trinomab&#8217;s Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Trinomab's Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China - Insight, China&#039;s Pharmaceutical Industry","description":"Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Retavibart Injection (formerly TNM001 Injection), a recombinant long\u2011acting fully human monoclonal antibody targeting respiratory syncytial virus (RSV). The product is specifically designed for infants under one year old, including high\u2011risk populations prone to severe RSV infections, for the prevention of lower respiratory tract infections caused by the virus.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57727","og_locale":"en_US","og_type":"article","og_title":"Trinomab's Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China","og_description":"Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Retavibart Injection (formerly TNM001 Injection), a recombinant long\u2011acting fully human monoclonal antibody targeting respiratory syncytial virus (RSV). The product is specifically designed for infants under one year old, including high\u2011risk populations prone to severe RSV infections, for the prevention of lower respiratory tract infections caused by the virus.","og_url":"https:\/\/flcube.com\/?p=57727","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-24T09:27:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57727#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57727"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Trinomab&#8217;s Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China","datePublished":"2026-02-24T09:27:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57727"},"wordCount":445,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57727#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2404.webp","keywords":["Trinomab Biotech"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57727#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57727","url":"https:\/\/flcube.com\/?p=57727","name":"Trinomab's Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57727#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57727#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2404.webp","datePublished":"2026-02-24T09:27:06+00:00","description":"Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Retavibart Injection (formerly TNM001 Injection), a recombinant long\u2011acting fully human monoclonal antibody targeting respiratory syncytial virus (RSV). The product is specifically designed for infants under one year old, including high\u2011risk populations prone to severe RSV infections, for the prevention of lower respiratory tract infections caused by the virus.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57727#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57727"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57727#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2404.webp","width":1080,"height":608,"caption":"Trinomab's Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57727#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Trinomab&#8217;s Retavibart NDA Accepted by NMPA \u2013 First Long\u2011Acting RSV mAb for Infant Protection in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57727"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57727\/revisions"}],"predecessor-version":[{"id":57730,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57727\/revisions\/57730"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57729"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}